Uncategorized

Uncategorized

New Releases from NCBI BookshelfElexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta): Indication: Treatment of cystic fibrosis in patients aged 2 years and older who have at least one mutation in the CFTR gene that is responsive based on clinical and/or in vitro data: Reimbursement Recommendation [Internet].​Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta): Indication: Treatment of cystic fibrosis in patients aged 2 years and older who have at least one mutation in the CFTR gene that is responsive based on clinical and/or in vitro data: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Trikafta be reimbursed by public drug plans for the treatment of cystic fibrosis (CF)

Uncategorized

New Releases from NCBI BookshelfAlectinib (Alecensaro): Indication: For adjuvant treatment following tumour resection for patients with stage IB (tumour ≥ 4 cm) to IIIA ALK-positive non–small cell lung cancer: Reimbursement Recommendation [Internet].​Alectinib (Alecensaro): Indication: For adjuvant treatment following tumour resection for patients with stage IB (tumour ≥ 4 cm) to IIIA ALK-positive non–small cell lung cancer: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Alecensaro should be reimbursed by public drug plans for adjuvant treatment following tumour resection

Scroll to Top